Pancreatic Cancer Research

ResearcherAlbert Einstein College of MedicineNo recent work listed

Andreas Kaubisch

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3410-664X; OpenAlex author ID A5001637416. Sources: ClinicalTrials.gov.

Their work

Papers
2
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2002: 1 trial · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper

Papers 2

  1. Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/10732748221134411↗
  2. The Neutrophil-to-Lymphocyte Ratio is a Prognostic Biomarker in An Ethnically Diverse Patient Population with Advanced Pancreatic Cancer. Co-author DOI 10.1007/s12029-019-00316-8↗

Trials 1

  1. Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer Principal investigator NCT00031694↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jennifer W. Chuy · 2 shared papers, 2020–2022 · strength 0.25
  2. Sanjay Goel · 2 shared papers, 2020–2022 · strength 0.25
  3. Ana Acuña-Villaorduña · 1 shared paper, 2022 · strength 0.15
  4. Michael Shusterman · 1 shared paper, 2020 · strength 0.11
  5. Justin Tang · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.